Jazz Pharmaceuticalsの空売り状況は、投資家がJazz Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報, 空売り情報

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

WIIM

JAZZ

Jazz Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $130 to $170.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Leerink Partners analyst Michael Cherny upgraded the rating for CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) from Market Perform to Outperform and raised the price target from $55 to $75. CVS Health shares closed at $63.22 on Wednesday. <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) from Underweight to Equal-Weight and boosted the price target from $85 to $89. DuPont shares closed at $81.76 on Wednesday. <a href="https://www.benzinga.com/quote/DD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Mohit Bansal upgraded the rating for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Equal-Weight to Overweight and raised the price target from $130 to $170. Jazz Pharmaceuticals shares closed at $135.44 on Wednesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Matthew Weston upgraded AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) from Neutral to Buy. AstraZeneca shares closed at $74.43 on Wednesday. <a href="https://www.benzinga.com/quote/AZN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Jeffrey Hung upgraded the rating for Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) from Equal-Weight to Overweight but lowered the price target from $70 to $67. Cytokinetics shares closed at $42.18 on Wednesday. <a href="https://www.benzinga.com/quote/CYTL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png" alt="" class="wp-image-780826" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13073343/image-117.png 1088w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CYTK

This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $181.11, a high estimate of $207.00, and a low estimate of $162.00. This current average has increased by 2.84% from the previous average price target of $176.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1739448038_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$207.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$207.00</td>
<td>$207.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$163.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$154.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Jazz Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Financial Insights: Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.52%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.39%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 5.42%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.82%, the company showcases efficient use of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 1.49, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)

Wells Fargo analyst Mohit Bansal upgrades Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from Equal-Weight to Overweight and raises the price target from $130 to $170.

Price Target

Wells Fargo Upgrades Jazz Pharmaceuticals to Overweight, Raises Price Target to $170

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board
Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue
Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025
DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within 12 months. Mr. Cozadd will retire as CEO once a successor has been appointed and will continue serving as Chairperson of the Board of Directors, providing ongoing leadership and strategic guidance to the Company. Jazz remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion.

Guidance

Management

Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24 Total Revenue Guidance Of Between $4B-$4.1B

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $163 price target.

Reiteration

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Maintains $163 Price Target

RBC Capital analyst Gregory Renza reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and maintains $179 price target.

RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $179 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

The majority of caregivers of patients with tuberous sclerosis complex (TSC) say they plan to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, announced by Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>). 
New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio">acquired by</a> Jazz Pharmaceuticals in 2021. 
Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved for treating seizures related to <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures">tuberous sclerosis complex</a>, a rare genetic disorder that causes non-cancerous tumors to grow in many parts of the body, including the brain, skin, heart, eyes, kidneys and lungs.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40527455/the-only-fda-approved-cbd-treatment-for-severe-epilepsy-completes-key-phase-3-trial-in-japan-des">The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
&#8220;Our real-world data presentations at AES 2024, including novel findings from the BECOME-LTC, BECOME-TSC and EpiCom studies, demonstrate the meaningful impact of Epidiolex in the treatment of patients with rare epilepsies,&#8221; said Sarah Akerman, MD, head of neuroscience global medical and scientific affairs of Jazz Pharmaceuticals. &#8220;These findings increase our understanding of Epidiolex&#8217;s benefits beyond seizure control, addressing unmet needs across a range of epilepsy syndromes for people living with rare epilepsies and demonstrating reproducibility and consistency of effect across different populations.&#8221;
Other highlights include:
<ul>
<li>Among 102 nurses surveyed, 85% reported a reduction in overall frequency of any seizure type after Epidiolex initiation, with 49% reporting a greater than 50% reduction, according to results from the BECOME-LTC survey.</li>
<li>Demonstrated reduced caregivers&#8217; need for additional support of their dependents&#8217; physical, emotional and behavioral care after Epidiolex initiation and characterized improvements in their dependents&#8217; well-being as well as caregivers&#8217; experiences, results from CARE-EpiC (Caregiver Analysis of Real-world Epidiolex in Epilepsy Context), a cross-sectional caregiver survey showed.</li>
<li>TSC-associated neuropsychiatric disorders (TAND)-associated outcomes demonstrated improvements after initiating adjunctive Epidiolex treatment in the severity of behavioral problems in patients with TSC as reported by the TAND Self-Report Quantified Checklist and Aberrant Behavior Checklist, according to the analysis of the EpiCom trial.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/02/30686971/cbd-based-life-changing-drug-for-tuberous-sclerosis-patients-epidiolex-now-available-via-england">CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England&#8217;s NHS</a></li>
</ul>

Cannabis

Health Care

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements

Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms
Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex&#xAE;)&nbsp;surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers
For U.S. media and investors only
DUBLIN, Dec. 6, 2024 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced nine company-sponsored Epidiolex&#xAE;&nbsp;(cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.
Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with&nbsp;Epidiolex. An additional presentation showcases data from the BECOME-LTC survey, which evaluated the perspectives of nurses who care for patients with epilepsy in long-term care (LTC) facilities and group homes, reporting improvements in seizure frequency and in certain non-seizure outcomes associated with Epidiolex treatment. Further, the first presentation of data from the EpiCom trial, a prospective, interventional trial evaluating the impact of adjunctive Epidiolex on TSC-associated neuropsychiatric disorders (TAND), revealed improvements in behavioral symptom severity following treatment initiation.

Biotech

General

Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting

Jazz Pharmaceuticals Announced That Zanidatamab-hrii (Ziihera) 50 Mg/Ml For Injection For Intravenous Use Is Recommended By The National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As A Category 2A Treatment Option For Biliary Tract Cancers

Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment
DUBLIN, Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from&nbsp;December 10-13 and 13 abstracts at the 66th Annual&nbsp;American Society of Hematology&nbsp;(ASH) Annual Meeting from&nbsp;December 7-10.

Jazz Pharmaceuticals To Present Advancements In Solid Tumors And Blood Cancer Research At San Antonio Breast Cancer Symposium And American Society Of Hematology Annual Meeting From December 7-10

On Tuesday, Axsome Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42185380/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-encore-long-term-phase-3-trial-i" rel="noreferrer noopener">Phase 3 ENCORE trial</a>.
AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials.
The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compared to a mean increase of 1.32 attacks per week for patients randomized to continue AXS-12 treatment at 3 weeks (p=0.017).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39891953/axsome-therapeutics-cns-portfolio-poised-for-major-growth-analyst-predicts-strong-f" rel="noreferrer noopener">Axsome Therapeutics&#8217; CNS Portfolio Poised for Major Growth &#8211; Analyst Predicts Strong Future</a>
AXS-12 resulted in statistically significant benefit in cognition compared to placebo.
A higher number of patients who switched to placebo experienced worsening on the NSAQ Ability to Concentrate item compared to those continuing on AXS-12 (52.6% versus 14.3%) at 3 weeks (p=0.011).
A statistically significant improvement in narcolepsy overall was observed compared to placebo.
More patients randomized to switch to placebo reported worsening of their narcolepsy compared to those continuing on AXS-12 (52.6% versus 16.7%) at 3 weeks (p=0.024).
During the long-term open-label treatment portion of the trial, patients experienced substantial and sustained improvement of cataplexy with AXS-12 treatment.
Patients experienced a 71% reduction from baseline in mean weekly cataplexy attacks at 1 month with AXS-12 treatment, which was sustained with long-term treatment, resulting in a 77% reduction at 6 months.
Long-term open-label treatment with AXS-12 resulted in substantial improvements in excessive daytime sleepiness. Mean scores were reduced by 5.6 points at 1 month, with this improvement maintained with long-term treatment, resulting in a mean reduction of 7.3 points at 6 months.
William Blair views the safety profile of AXS-12 as a key differentiator from Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Xyrem. The analyst reiterates the Outperform rating on Axsome.
&#8220;Ultimately, we believe AXS-12 is both an approvable and effective therapy, with the data released today building on both the efficacy and long-term safety of the product,&#8221; the analyst writes.
William Blair conservatively models $440 million in peak AXS-12 sales, relative to growing Wakix sales of $582 million in 2023, and says the asset is undervalued with investor focus on data for AXS-05 in Alzheimer's disease agitation expected before year-end.
Price Action: AXSM stock is up 2.5% at $99.46 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42216863/nvidia-intel-suppliers-rethink-mexico-operations-amid-trumps-tariff-threat" target="_blank" rel="noreferrer noopener">Nvidia, Intel Suppliers Rethink Mexico Operations Amid Trump&#8217;s Tariff Threat</a></li>
</ul>
Image via Pixabay.

Analyst Color

Equities

AXSM

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Large Cap

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $163.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $163

Jazz Pharmaceuticals and Zymeworks shares are trading higher after announcing their Zihera collaboration secured FDA approval to treat HER2-positive biliary tract cancer in adults.

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of
<ul>
<li>Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.</li>
<li>Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial</li>
<li>Company to host investor webcast on Dec. 11, 2024</li>
</ul>
In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as Jazz), for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the Company to leverage Jazz's global commercial infrastructure, together with BeiGene's complementary strengths in certain Asia Pacific countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with difficult-to-treat cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.

Reported Earlier, Jazz Pharmaceuticals Secures FDA Approval For Ziihera (zanidatamab-hrii) To Treat HER2-Positive Biliary Tract Cancer In Adults

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out… In the fast-growing biotechnology sector, driven by advances in gene editing, personalized medicine, and artificial intelligence, companies are racing to develop new treatments for an aging population and the increasing demand for healthcare. Among the innovators in this space, Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) is gaining significant attention, and for good reason.
Exelixis is zeroing in on difficult-to-treat cancers armed with a clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs), and other biotherapeutics. The company leverages cutting-edge science, strategic collaborations, and significant investments to broaden its reach across various tumor types.
EXEL delivered exceptional results in its fiscal <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-third-quarter-2024-financial-results-and">third quarter</a>, surpassing analyst expectations while demonstrating the strength of its cancer-focused portfolio. The company's flagship product, CABOMETYX&#xAE;, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting FDA approvals, EXEL is relentlessly working to improve treatment options.
In terms of price performance, the stock has returned 17.4% in the past three months, while over the past year, it rose by an impressive 47.9%, closing the last trading session at $32.73.
As we look ahead, 2025 could be a defining year for Exelixis. With a robust pipeline and an ongoing push for innovation, this company is on track for more clinical and regulatory milestones. But is EXEL a biotech stock worth adding to your portfolio?
Let's explore the factors that could shape the company's performance in the near future.
A Robust Pipeline Beyond Cabometyx
Exelixis isn't resting on its laurels with the success of CABOMETYX&#xAE;. The company is aggressively expanding its oncology portfolio with promising candidates like zanzalintinib, a next-generation oral tyrosine kinase inhibitor (TKI). This drug is being tested in the STELLAR-303 study, where it's combined with Tecentriq to treat advanced colorectal cancer. With enrollment now complete, early results from this pivotal trial are anticipated in 2025, potentially opening new doors for treatment options in a challenging cancer type.
Adding to its momentum, EXEL recently <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-merck-sign-clinical-development-collaboration">partnered</a> with pharmaceutical heavyweight Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) to explore zanzalintinib's potential combined with MRK's blockbuster PD-1 therapy Keytruda (pembrolizumab). This collaboration spans several studies, including a late-stage trial for head and neck squamous cell carcinoma (HNSCC) and a phase I/II trial using Merck's hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, Welireg, for renal cell carcinoma (RCC).
By diversifying its pipeline, EXEL is reducing its reliance on CABOMETYX&#xAE; and aiming for long-term growth. These efforts could pave the way for a new wave of therapies that improve outcomes for cancer patients worldwide.
Robust Financials and Upbeat Guidance
During the third quarter that ended September 30, 2024, EXEL's total revenue increased 14.3% year-over-year to $539.54 million. Its income from operations income came in at $136.07 million compared to a year-ago loss of $17.58 million.
In addition, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $135.66 million or $0.47 per share, reflecting a considerable improvement from $32.09 million or $0.10 per share, respectively, recorded in the same period last year.
Recently, the company announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for the fiscal year 2025, and delivered an update on its business. Total revenues are projected to be between $2.15 billion and $2.25 billion (previous guidance: $1.975-$2.075 billion). Net product revenues are estimated to be in the band of $1.95-$1.2.05 billion (previous guidance: $1.65-$1.75 billion).
Solid Historical Growth
EXEL's revenue and EBITDA have grown at respective CAGRs of 18.4% and 45% over the past three years. The company's EBIT has increased 46.3% over the same timeframe, while its net income and EPS have improved at CAGRs of 41.7% and 44.8%, respectively.
Also, the company's total assets and levered free cash flow have grown at CAGRs of 6.5% and 25.6% over the past three years, respectively.
Favorable Analyst Estimates
Analysts expect EXEL's EPS for the fourth quarter (ended December 2024) to increase 56.7% year-over-year to $0.42. Its revenue for the same quarter is expected to come in at $558.60 million, reflecting a growth of 16.5% from the prior year. Furthermore, the company has surpassed the consensus EPS and revenue estimates in three of the trailing four quarters, which is promising.
Additionally, Street expects the company's revenue and EPS for the fiscal year (ending December 2025) to increase 3.6% and 8.6% year-over-year to $2.23 billion and $1.89, respectively.
High Profitability
EXEL's trailing-12-month gross profit margin of 96.25% is 65.9% higher than the respective industry average of 58%. Its trailing-12-month EBIT margin of 29.22% is significantly higher than the industry average of 2.39%.
Furthermore, the stock's trailing-12-month net income, ROCE, and ROTA of 22.43%, 20.20%, and 15.77% favorably compare to the negative industry averages of 4.61%, 40.27%, and 26.01%, respectively. Similarly, its trailing-12-month levered FCF margin of 20.72% is considerably higher than the industry average of 2.50%.
POWR Ratings Reflect Promise
EXEL's robust prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. EXEL has an A grade for Value and Quality, which is in sync with its lower-than-industry valuations and robust profitability, respectively.
Also, the stock has a B grade for Growth, consistent with its strong financial performance and historical growth.
Among the 333 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, EXEL is ranked #3. Beyond what I have stated above, we have also given EXEL grades for Momentum, Sentiment, and Stability. Get access to all the EXEL ratings <a href="https://stocknews.com/stock/EXEL/">here</a>.
Bottom Line
EXEL reported better-than-expected financial results for the third quarter. Analysts appear bullish about the company's growth prospects, driven by robust demand for its quality and diverse product offerings, expanding pipeline, strategic collaborations, and strong market position. Also, its growing revenue and gross profit margin depict solid financial health.
Given EXEL's solid financials, accelerating profitability, and promising growth outlook, this stock could be an ideal buy now.
How Does Exelixis, Inc. (EXEL) Stack Up Against Its Peers?
While EXEL has an overall POWR Rating of A, investors could also check out these other stocks within the Biotech industry with A (Strong Buy) or B (Buy) ratings: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>), and Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>).
For exploring more A and B-rated biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
EXEL shares were trading at $32.83 per share on Tuesday afternoon, up $0.10 (+0.31%). Year-to-date, EXEL has declined -1.41%, versus a 3.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/exel-gild-jazz-otsky-mrk-is-exelixis-a-biotech-stock-worth-adding-to-your-portfolio/>Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

SPLG: S&P 500 Dashboard For February

Harmony Biosciences' (HRMY) recently released growth plans and pipeline advancements have showcased the company's dedication towards being a top contender in the highly contested biotech market. So, should investors looking to capitalize on the industry's prospects consider investing in HRMY? Read more… Last month, Harmony Biosciences Holdings Inc. (<a href="https://stocknews.com/stock/HRMY/">HRMY</a>), a dedicated pharmaceutical firm specializing in innovative therapies for rare neurological diseases, revealed robust preliminary, unaudited <a href="https://ir.harmonybiosciences.com/node/9321/pdf">net product revenues of $201 million</a> for the fourth quarter of fiscal 2024 and $714 million for the full year.
HRMY's impressive performance paves the way for a dynamic 2025, packed with value-driving milestones each quarter. With a sharp focus on maximizing its neuroscience pipeline, the company enters the year with unstoppable momentum, charting a clear course toward sustained growth and a potential $3 billion in future net revenue.
That said, shares of HRMY have surged 17.8% over the past three months and 24.7% over the past nine months, closing the last trading session at $39.36.
So, let us discuss the factors that could affect the stock's growth trajectory.
Stable Historical Growth
HRMY's prospects are quite apparent from its consistent growth across key financial metrics. Its revenue and EBITDA grew at a CAGR of 36.1% and 32.9%, respectively. The company's operation income and total assets also expanded at a CAGR of 38% and 33.4%, respectively.
Moreover, net income and EPS expanded at a CAGR of 119% and 120.7%, respectively, over the same period.
Sound Financials
During the fiscal third quarter that ended September 30, 2024, HRMY's net product revenue increased 16.1% year-over-year to $186.04 million. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> amounted to $61.71 million.
Moreover, the company's non-GAAP adjusted net income and non-GAAP adjusted net income per share rose 1.4% and 6.2% from the prior year's quarter to $59.60 million and $1.03, respectively. As of September 30, 2024, HRMY's cash and cash equivalents amounted to $387.37 million, compared to $311.66 million on December 31, 2023.
Optimistic Analyst Estimates
Analysts expect HRMY's revenue and EPS for the fiscal 2024 fourth quarter that ended December 2024 to increase 19.7% and 60.3% year-over-year to $201.51 million and $0.72, respectively. In addition, the company exceeded the consensus revenue estimates in each of the four trailing quarters, which is impressive.
For the fiscal 2025 first quarter ending in March, HRMY's revenue and EPS are expected to rise 18.3% and 1.3% from the prior year's period to $182.92 million and $0.68, respectively.
Robust Profitability
HRMY's trailing-12-month gross profit margin of 78.65% is 35.1% higher than the industry average of 58.20%. Its trailing-12-month EBITDA margin stands at 29.27%, 406.7% higher than the industry average of 5.78%.
In addition, the company boasts a trailing-12-month levered FCF margin of 24.73%, which is 926.1% higher than the sector average of 2.41%. Also, the stock's trailing-12-month asset turnover ratio of 0.80x is 93.7% higher than the industry average of 0.41x.
Discounted Valuation
HRMY is currently trading at a forward non-GAAP P/E of 11.64x, which is 43.6% lower than the industry average of 20.65x. Moreover, the stock's forward EV/EBIT multiple stands at 9.82, 41.3% lower than the industry average of 16.74x.
Additionally, it has a forward Price/Sales multiple of 3.14, which is 14.6% lower than the industry average of 3.68x. This indicates that HRMY is undervalued compared to its peers, offering potential upside for investors.
POWR Ratings Reflects Optimism
HRMY's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
HRMY has an A grade for Value, driven by its discounted valuation metrics relative to the industry average. It also earns an A for Quality, in line with its higher-than-average profitability metrics.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, HRMY is ranked #9 out of 336 stocks. Beyond what is stated above, we have also given HRMY grades for Momentum, Sentiment, Growth, and Stability. Get all HRMY ratings <a href="https://stocknews.com/stock/HRMY/">here</a>.
Bottom Line
HRMY has successfully drawn out an impressive development plan for the ongoing fiscal year that includes potential approvals, increased revenue growth, and positive clinical trial data. The company expects up to six phase 3 clinical development programs by the end of 2025 and the current pipeline to generate billions in net revenue.
Additionally, HRMY anticipates delivering at least one new product or indication approval every year for the next four years. With such a clear course toward sustained growth, the company is well-poised to deliver impressive results in the year to come. Given HRMY's solid financials, attractive valuation, and high profitability, now could be the ideal time to invest in the stock.
How Does Harmony Biosciences Holdings, Inc. (HRMY) Stack Up Against Its Peers?
Although HRMY's near-term outlook appears sound, it may be worthwhile to explore its industry peers, who also exhibit strong POWR Ratings. So, consider these A (Strong Buy) rated stocks from the Biotech industry:
Gilead Sciences Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>)
Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
To explore more A or B-rated Biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
HRMY shares were unchanged in premarket trading Thursday. Year-to-date, HRMY has gained 14.39%, versus a 3.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aritra_Gangopadhyay</h2> <img src='https:/wp-content/uploads/2025/01/Aritra_Gangopadhyay.png' style="float:left; padding:5px;width:125px;">Aritra is a financial journalist dedicated to breaking down complex financial topics into simple, actionable insights. Holding a Master's degree in Economics, he uses his analytical expertise to help investors uncover unique opportunities for long-term success.<a href="https://stocknews.com/authors/?author=aritra-gangopadhyay">More...</a>The post <a href=https://stocknews.com/news/hrmy-gild-gmab-jazz-is-harmony-biosciences-holdings-inc-hrmy-a-biotech-stock-to/>Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Harmony Biosciences Holdings Inc. (HRMY) a Biotech Stock to Consider?

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price...

Morgan Stanley Remains a Buy on Jazz Pharmaceuticals (JAZZ)

Zymeworks: Its Post-Approval Future

Avadel Pharmaceuticals gains as holder pushes for sale process

Avadel Pharmaceuticals: Moving To A Speculative Buy

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz Pharmaceuti...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ) and PTC Therapeutics (PTCT)

Wells Fargo analyst Mohit Bansal upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $170, up from $130. Th...

Jazz Pharmaceuticals upgraded to Overweight from Equal Weight at Wells Fargo

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Target downgraded, Cisco upgraded: Wall Street's top analyst calls

APOG

AVDL

CRSP

CSCO

EXEL

EXPE

GILD

GMAB

HRMY

HUBS

LMAT

MRUS

OTSKY

PTCT

SPLG

VKTX

Earnings

Press Releases

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz Pharmaceuticals Announces CEO Succession Plan

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

空売り

Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル